The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...
Upstream Bio’s (NASDAQ:UPB – Get Free Report) lock-up period will end on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th. The total size ...
A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic rhinosinusitis.
A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to ...
Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...
Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...
The following is a summary of "Clinical characteristics and management of long survivors in extensive stage small cell lung ...
The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...
The study results demonstrate the ability to improve the sense of smell with noninvasive devices in different types of users.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback